Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (9)
  • Until platform closure (22)
Poster categories
  • Thematic Poster Session (36)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • L-TPS04 (13)
  • L-TPS05 (10)
  • L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • x TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • x TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • x TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
36 results
Thumbnail

D1.33 - Patient-reported outcomes following beta-lactam antibiotic allergy delabeling work-up

Thumbnail

D1.34 - Guideline adherence and safety of AI chatbots in allergology

Thumbnail

D1.37 - Which Came First? Atopic Dermatitis or occupational Allergic Contact Dermatitis in a Surgeon with Tropomyosin-Driven IgE Cross-Reactivity

Thumbnail

D1.38 - A Generalizable High-Throughput Nanobody Discovery Platform for Airborne Allergens

Thumbnail

D1.39 - Oral Lichenoid Lesions Secondary to Contact Allergy to L-Carvone from Toothpaste: A Case Report

Thumbnail

D1.40 - Independent Sensitization to poultry meat and tuna in a food allergic young girl

Thumbnail

D1.41 - B cell responses to alarmins in type 2 inflammation

Thumbnail

D1.42 - Unusual Delayed Hypersensitivity Reaction to Different Antibiotic Families

Thumbnail

D1.44 - Primary care allergy and clinical immunology fellowship: A Delphi study of core competencies

Thumbnail

D1.45 - Selective Anaphylaxis to Salmonids with Tolerance to Other Fish

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study

Thumbnail

D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research

Thumbnail

D1.115 - Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM